Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON MILLER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1285746974
CMS profile
194371
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$34.37

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $34.37 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $19.77 1
Allergan, Inc. $14.60 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON MILLER

NPI 1285746974 · CMS profile ID 194371

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1285746974?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285746974?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JASON MILLER, NPI 1285746974, CMS profile ID 194371. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285746974?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JASON MILLER, NPI 1285746974, CMS profile ID 194371, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1285746974?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $34.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Allergan, Inc. $14.6010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792875769 CMS
Janssen Pharmaceuticals, Inc $19.7702/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788076917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110.01 6
PY2020 $45.14 2
PY2021 $34.37 2
PY2023 $36.85 2
PY2025 $135.98 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $17,303.33 9
PY2020 Principal investigator $117,506.77 50
PY2019 Principal investigator $733,525.99 145

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $2,946.08 12/31/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314347
Principal investigator 1 Allergan, Inc. $300.00 12/31/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721318509
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,450.00 12/10/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION (IA) IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749583749
Principal investigator 1 Allergan, Inc. $86.00 07/30/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721287611
Principal investigator 1 Allergan, Inc. $500.00 07/22/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721286119
Principal investigator 1 Allergan, Inc. $1,000.00 07/22/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721286121
Principal investigator 1 Eisai Inc. $438.65 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749133321
Principal investigator 1 Eisai Inc. $250.00 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749134251
Principal investigator 1 Eisai Inc. $750.00 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749134253
Principal investigator 1 Eisai Inc. $650.00 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749135427
Principal investigator 1 Eisai Inc. $13,982.00 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749135491
Principal investigator 1 Supernus Pharmaceuticals, Inc. $20,010.43 07/21/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749582919
Principal investigator 1 Allergan, Inc. $350.00 07/07/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721282973
Principal investigator 1 Allergan, Inc. $600.00 07/07/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721282975
Principal investigator 1 Allergan, Inc. $3,533.05 06/18/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721280781
Principal investigator 1 Supernus Pharmaceuticals, Inc. $3,121.93 05/14/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582581
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,603.17 04/20/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749582295
Principal investigator 1 Supernus Pharmaceuticals, Inc. $6,396.67 04/20/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582329
Principal investigator 1 Allergan, Inc. $409.40 04/13/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269441
Principal investigator 1 Allergan, Inc. $169.00 04/09/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269235
Principal investigator 1 Allergan, Inc. $1,500.00 04/09/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721269379
Principal investigator 1 Eisai Inc. $2,041.00 03/24/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749133143
Principal investigator 1 Eisai Inc. $1,797.00 03/24/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749133325
Principal investigator 1 Genentech, Inc. $50.00 03/24/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
PRODROMAL TO MILD AD No dispute reported 06/30/2026 743046061
Principal investigator 1 Allergan, Inc. $8,306.80 03/19/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721266047
Principal investigator 1 Allergan, Inc. $7,066.10 03/19/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721266211
Principal investigator 1 Supernus Pharmaceuticals, Inc. $30.00 03/19/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION (IA) IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749582145
Principal investigator 1 Supernus Pharmaceuticals, Inc. $30.00 03/19/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582149
Principal investigator 1 Supernus Pharmaceuticals, Inc. $250.00 03/19/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749582151
Principal investigator 1 Allergan, Inc. $327.00 03/12/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
AN OPEN LABEL, LONG TERM-EXTENDED ACCESS PROTOCOL FOR RAPASTINEL AS ADJUNCTIVE OR MONOTHERAPY TREATMENT IN PATIENTS WITH MAYOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721263277
Principal investigator 1 Allergan, Inc. $2,314.20 02/24/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721258953
Principal investigator 1 Supernus Pharmaceuticals, Inc. $90.00 02/11/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
ASSESSMENT OF EFFICACY AND SAFETY OF SPN-810 FOR THE TREATMENT OF IMPULSIVE AGGRESSION (IA) IN ADOLESCENT SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749581923
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,834.51 02/05/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC SUBJECTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER No dispute reported 06/30/2026 749581873
Principal investigator 1 Allergan, Inc. $2,500.00 02/03/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721254909
Principal investigator 1 Allergan, Inc. $2,500.00 02/03/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721254911
Principal investigator 1 Allergan, Inc. $385.00 01/28/2020 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY OF RAPASTINEL AS ADJUNCTIVE THERAPY IN THE PREVENTION OF RELAPSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER No dispute reported 06/30/2026 721251171
Principal investigator 1 Eisai Inc. $1,470.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133217
Principal investigator 1 Eisai Inc. $2,904.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133219
Principal investigator 1 Eisai Inc. $1,596.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133221
Principal investigator 1 Eisai Inc. $1,470.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133331
Principal investigator 1 Eisai Inc. $1,470.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133333
Principal investigator 1 Eisai Inc. $2,904.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133335
Principal investigator 1 Eisai Inc. $1,470.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133337
Principal investigator 1 Eisai Inc. $2,071.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133339
Principal investigator 1 Eisai Inc. $1,773.00 01/28/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 749133341
Principal investigator 1 Supernus Pharmaceuticals, Inc. $1,000.00 01/14/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLINDONE HYDROCHLORIDE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF IMPULSIVE AGGRESSION IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CONJUNCTION WITH STANDARD ADHD TREATMENT No dispute reported 06/30/2026 749581743
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $400.00 01/03/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE LONGER-TERM (IE, MAINTENANCE) EFFICACY OF ORAL ARIPIPRAZOLE IN THE TREATMENT OF PEDIATRIC SUBJECTS WITH TOURETTE'S DISORDER No dispute reported 06/30/2026 748802803
Principal investigator 1 Eisai Inc. $1,543.00 01/02/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 749133207
Principal investigator 1 Eli Lilly and Company $7,845.20 01/02/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728737857
Principal investigator 1 Eli Lilly and Company $22.58 01/02/2020 Non-covered Recipient Entity
CLINICAL TRIALS OF TEXAS INC
AN OPEN LABEL, LONG TERM, SAFETY STUDY OF LASMIDITAN 100 MG AND 200 MG IN THE ACUTE TREATMENT OF MIGRAINE GLADIATOR No dispute reported 06/30/2026 728739807